UnitedHealth’s New CEO Receives $60 Million Compensation Package Amid Controversies
On Monday, UnitedHealth’s investors greenlit a significant payroll package for its new CEO, including a hefty $60 million in stock options. This decision comes at a time when the company is grappling with financial difficulties, alongside allegations of criminal fraud and the shocking murder of a high-ranking executive.
Stephen Hemsley, who previously held the CEO position for nearly a decade until 2017, stepped back into the role last month, following the healthcare company’s first revenue miscalculation since 2008.
In addition to the future stock award, which will vest in three years, Hemsley will receive an annual salary of $1 million.
A representative for UnitedHealth stated that “Steve Hemsley’s compensation is in line with the median for CEOs at similar companies and aligns with the interests of shareholders.”
This new compensation package marks Hemsley’s return after Andrew Whitty’s resignation last month after leading the company for four years.
Despite recent turmoil, the company’s market capitalization has risen more than 50% since its peak in November, crossing the $250 billion mark.
In a recent statement, UnitedHealth emphasized its commitment to taking necessary steps to provide outstanding services and positive outcomes for customers, consumers, and healthcare providers.
The company faced a significant blow last December with the execution-style murder of Brian Thompson, its insurance branch leader, in midtown Manhattan. The accused killer, Luigi Mangione, has pleaded not guilty, with his trial set for 2026.
Shareholders have since filed a lawsuit against UnitedHealth, claiming the company concealed the negative impacts following Thompson’s murder, suggesting it adversely affected business operations.
A class action lawsuit filed in Manhattan federal court claimed that after Thompson’s death, UnitedHealth shifted away from strategies that often resulted in claim denials without disclosing how this affected profitability.
Moreover, UnitedHealth is reportedly under investigation by the Department of Justice, according to the Wall Street Journal.
A spokesperson for UnitedHealth refuted this claim, deeming the report “deeply irresponsible,” stating they had not been officially notified by the Department of Justice.
On Monday, the stock prices remained relatively stable, reflecting a considerable decline of around 40% this year.
A major drop occurred on April 17, when shares plummeted 22%, erasing approximately $119 billion from the market value after insurers downgraded their profit forecasts for 2025.
During the annual shareholders’ meeting, Hemsley acknowledged the company’s performance issues, expressing a commitment to restoring trust among investors.
In an effort to address the situation, UnitedHealth plans to review its policies and practices concerning risk assessments, managed care, and pharmacy services, brought before independent experts, Hemsley noted.
There has been noticeable discontent among investors, especially in light of the optimistic outlook provided just months earlier by former CEO Andrew Whitty.
Interestingly, Whitty’s approach involved less conventional leadership traits, including a more casual office attire and a relaxed meeting format. However, this style may have contributed to some of UnitedHealth’s recent struggles.
The government implemented new payment rules that affected Medicare insurance companies, notably limiting favorable payments for certain diagnoses, which had previously benefitted UnitedHealth.
With changes in 2023 cutting off advantageous payments, these new regulations are set to take effect next year, adding to the company’s challenges ahead.
